Marker Therapeutics, Inc. reports developments as a clinical-stage immuno-oncology company developing non-genetically modified Multi-Antigen Recognizing T cell therapies for hematologic malignancies and solid tumor indications. Its recurring company updates center on the MAR-T cell platform, MT-601 in lymphoma, MT-401-OTS as an off-the-shelf program, and pancreatic cancer research connected to technology developed at Baylor College of Medicine.
Company news also covers clinical observations from named studies, non-dilutive funding from government and cancer-research programs, scientific publications and medical-meeting presentations, quarterly financial results, conference participation, shareholder voting matters, and board governance changes.
Marker Therapeutics (Nasdaq: MRKR) — Oct 6, 2025 announced the first patient was treated in the Phase 1 RAPID study testing MT-401, a multi-antigen recognizing (MAR) T cell off-the-shelf (OTS) product.
The first participant received the initial dose of 100x10^6 cells and was monitored for 28 days; the therapy was reported as well tolerated with no treatment-related adverse events. The OTS program initially targets AML and MDS and may expand to other indications. Marker said commercially sourced leukapheresis from healthy donors could enable treatment as fast as 72 hours. The program is supported by non-dilutive funding from the FDA, NIH SBIR, and CPRIT.
Marker Therapeutics (NASDAQ:MRKR), a clinical-stage immuno-oncology company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.
CEO Dr. Juan Vera will lead a fireside chat on September 10, 2025, from 12:30 to 1:00 p.m. EDT at the Lotte New York Palace Hotel. The management team will also conduct one-on-one meetings with investors to discuss their MAR T cell platform and clinical developments, including updates from the Phase 1 APOLLO study.
Investors can access the webcast through Marker's Investor Relations website under "Events and Presentations".
Marker Therapeutics (NASDAQ:MRKR) has reported encouraging results from its Phase 1 APOLLO study investigating MT-601, a Multi-Antigen Recognizing T cell product, for treating relapsed lymphoma. The study demonstrated a 66% objective response rate in Non-Hodgkin Lymphoma (NHL) patients, with 50% achieving complete response.
The trial included 24 B-cell lymphoma patients across 7 U.S. clinical sites, with doses ranging from 100x106–400x106 cells. Notable outcomes include 78% objective response rate in Hodgkin Lymphoma patients and durable responses lasting 3-24 months. The treatment showed a favorable safety profile with no dose-limiting toxicities or serious adverse events.
The company is advancing to the dose expansion phase, investigating MT-601 at the maximum dose of 400x106 cells in DLBCL patients who have relapsed after or are ineligible for CAR-T therapy.
Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. CEO Dr. Juan Vera will engage in a fireside chat on August 12, 2025, from 12:30 to 12:55 p.m. EDT at the InterContinental Boston Hotel.
During the conference, management will conduct one-on-one meetings with investors to discuss their Multi-Antigen Recognizing (MAR) T cell platform and clinical developments. Investors can access the webcast through Marker's IR website under "Events and Presentations".
Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, has announced its participation in Canaccord Genuity's Horizons in Oncology Virtual Conference. CEO Dr. Juan Vera will join a panel discussion titled 'CAR-T in Solid Tumors and New T-cell Approaches – Breakthroughs Ahead?' scheduled for April 7, 2025, from 11:00 AM to 11:50 AM ET.
The company specializes in developing next-generation T cell-based immunotherapies for treating hematological malignancies and solid tumors. Their innovative platform features multi antigen recognizing (MAR)-T cell therapy, designed to simultaneously target multiple tumor-associated antigens. This approach has demonstrated promising clinical results in both hematologic malignancies and solid tumors.
Marker Therapeutics (MRKR) reported its 2024 year-end results, highlighting significant progress in its lead program MT-601. The company's Phase 1 APOLLO study demonstrated promising results with a 78% objective response rate in lymphoma patients, including 44.4% complete responses. The therapy showed a favorable safety profile with minimal side effects.
MRKR secured $13 million in non-dilutive funding from CPRIT and NIH SBIR, and raised $16.1 million through a private placement. The company ended 2024 with $19.2 million in cash, expecting to fund operations into Q1 2026. Financial results showed R&D expenses of $13.5 million (up from $10.4M in 2023) and a net loss of $10.7 million (compared to $8.2M in 2023).
Marker Therapeutics (Nasdaq: MRKR), a clinical-stage immuno-oncology company, announced that its President and CEO, Dr. Juan Vera, will present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. This event will take place on February 25, 2025.
Dr. Vera is scheduled to present an overview of Marker’s technology and clinical developments on Tuesday, February 25, 2025, at 3:30 PM Eastern Time (ET). Registered participants can access the presentation through the event portal on the day of the event.